HHS Proposes Sweeping Changes to AKS and Stark Law, Part 1: Value-Based Arrangements

Mintz - Health Care Viewpoints

Mintz - Health Care Viewpoints

As we reported last week, the Department of Health & Human Services (HHS) recently issued two proposed rules (one by the Office of Inspector General (OIG) and one by the Centers for Medicare & Medicaid Services (CMS)) that, if finalized, would implement sweeping changes to the Anti-Kickback Statute (AKS) and the Physician Self-Referral Law (commonly known as the Stark Law). One articulated aim of these proposed rules is to ease restrictions on and eliminate obstacles to value-based contracting, which the Trump administration supports. As Congress and Administration officials have been evaluating the future of value-based contracting, health care providers and payors have been clamoring for relief under existing fraud and abuse laws that they argue hinder value-based arrangements that could facilitate improved quality of care as well as lower costs. 

The proposed rules seek to reduce barriers to value-based arrangements in several ways, including: (1) creating new safe harbors to the AKS; (2) adding new exceptions to the Stark Law; and (3) retooling existing AKS safe harbors, along with the Civil Monetary Penalties rules regarding beneficiary inducements. Below are key takeaways from both the OIG’s and the CMS’s proposed rules as they relate to the new value-based arrangements safe harbors and Stark Law exceptions. Given the scope of the proposed amendments to the existing safe harbors and the CMP rules, we will cover those proposals in a separate, forthcoming blog post. 

Proposed New AKS Safe Harbors for Value-Based Arrangements

The OIG’s proposed rule would establish three new AKS safe harbors to address various care coordination and value-based care and payment arrangements. With these proposed safe harbors comes new value-based terminology. The safe harbors are generally designed to protect certain arrangements entered into with or by a “value-based enterprise,” or VBE. VBE is broadly defined to capture any number of network arrangements where the participants have agreed to collaborate for value-based purposes. To qualify for safe harbor protection, a VBE would need to have two or more participants that are parties to a value-based arrangement, as well as an accountable body (e.g., board of directors) or person that is responsible for oversight of the VBE. It would be required to adopt a governing document describing the VBE and how its participants will achieve its value-based purposes.

"Value-based” is used generally in the proposed rule as a qualifier to denote value created through improved care coordination or health outcomes, lower costs or reduced cost growth for patients and payors, and improved efficiencies in care delivery. If a “value-based arrangement” satisfied all conditions of an applicable proposed safe harbor, remuneration exchanged pursuant to that arrangement would be protected. The proposed rule defines a “value-based arrangement” as “an arrangement for the provision of at least one value-based activity for a target patient population between or among: (A) the value-based enterprise and one or more of its VBE participants; or (B) VBE participants in the same value-based enterprise.”

Importantly, not all entities involved in the provision of health care services or goods would be eligible to become VBE participants. There are a number of notable exceptions to the types of entities that could make use of the protections afforded by the three proposed safe harbors. A VBE participant is defined in the proposed rule as an individual or entity that engages in at least one value-based activity as part of a value-based enterprise. It could be, for example, a hospital, physician practice, payor, or social services organization. However, the proposed rule expressly excludes the following types of entities from the definition of "VBE participant": pharmaceutical manufacturers; manufacturers, distributors, or suppliers of durable medical equipment, prosthetics, orthotics, or supplies (DMEPOS); and laboratories. The OIG explains that it views these entities as playing different roles in the delivery of health care goods and services that raise special fraud and abuse concerns. For similar reasons, it is also considering excluding pharmacies, pharmacy benefits managers (PBMs), wholesalers, and distributors from the definition of VBE participant. The OIG seeks comments on whether the proposed exclusions are appropriate and acknowledges that it may need to address safe harbor protections for value-based arrangements by the excluded entities in a future rulemaking.

Proposed safe harbor for care coordination arrangements to improve quality, health outcomes, and efficiency

The first of the three proposed safe harbors would protect certain care coordination arrangements where the participating individuals or entities are not assuming financial risk. Protection would be limited to in-kind remuneration exchanged between qualifying VBE participants with value-based arrangements that meet all of the safe harbor’s requirements. Because this proposed safe harbor does not require the participants to assume downside financial risk, the OIG has built in a variety of conditions and safeguards to mitigate the risk of fraud and abuse. For example, the value-based arrangement would need to be commercially reasonable, with the terms of the arrangement set out in writing. The offeror of the remuneration could not take into account the volume or value of patient referrals or business generated that is not covered under the value-based arrangement. VBE participants would need to establish specific, evidence-based outcome measures against which the recipient of remuneration would be measured, and the remuneration exchanged would need to be used primarily to engage in value-based activities related to care coordination and management for the target patient population. The conditions for this safe harbor also include a requirement that the recipient of the in-kind remuneration pay at least 15% of the offeror’s cost for the remuneration.

Monitoring, assessment, and reporting requirements would also apply in order for the value-based arrangement to receive protection. It is worth noting that the VBE participants would be required to terminate their value-based arrangement if the required monitoring and assessment activities resulted in a determination by the VBE that the arrangement: (1) is unlikely to further the coordination and management of care for the target patient population; (2) has resulted in material deficiencies in quality of care; or (3) is unlikely to achieve the evidence-based, valid outcome measure(s).

This care coordination safe harbor would not protect ownership or investments interests in the VBE, or remuneration funded by or resulting from contributions of third parties who are not in the VBE. Additionally, to be protected, the remuneration cannot induce limitations on, or reductions of, medically necessary items or services furnished to any patient.

Proposed safe harbor for value-based arrangements with substantial downside financial risk

Unlike the proposed care coordination arrangements safe harbor above, the value-based arrangements with substantial downside financial risk safe harbor would protect both in-kind and monetary remuneration. As its name indicates, this proposed safe harbor is designed to provide more flexibility for arrangements where the VBE assumes substantial downside financial risk and the VBE participants meaningfully share in that risk. The proposed rule sets out several methodologies for determining whether a VBE is at substantial downside financial risk, along with criteria for what constitutes “meaningfully sharing” in that risk. For example, “meaningfully sharing” could include (subject to certain exceptions) an arrangement that provides for a partial or full capitated payment to the VBE participant.  

Remuneration would only be protected under this proposed safe harbor if: (1) the VBE participant receiving the remuneration primarily uses it to engage in value-based activities that are directly connected to the items and services for which the VBE is at substantial downside financial risk; and (2) the remuneration is directly connected to one or more of the VBE’s value-based purposes. Like the first safe harbor above, the remuneration could not encourage limitations on, or reductions of, medically necessary items or services furnished to patients.

Ownership or investment interests in the VBE or related distributions would not be protected under this proposed safe harbor. Remuneration from, or generated by contributions from, parties outside the VBE would also be excluded from protection.   

Proposed safe harbor for value-based arrangements with full financial risk

Of the three new proposed safe harbors, the value-based arrangements with full financial risk safe harbor is designed to afford the most flexibility to VBEs and VBE participants. It would protect monetary or in-kind remuneration from a VBE to a VBE participant, but not remuneration between or among VBE participants who are part of the same VBE or remuneration from a VBE participant to downstream contractors. To qualify for protection under this proposed safe harbor, a VBE would need to: (1) assume financial responsibility for the cost of all items and services covered by a payor for each patient in the target population; and (2) be paid prospectively by the payor.

A VBE at full financial risk could be, for example, a VBE that contracts with a Medicaid managed care organization, where the VBE is paid a fixed PMPM amount that covers the cost of all items and services covered by Medicaid and furnished to the target patient population. Arrangements whereby the VBE receives a partial capitated payment would not be protected. Additionally, an arrangement would not qualify for protection if the VBE participant could seek additional payment from a payor for items or services furnished to the target patient population.

As with the other two proposed value-based safe harbors, this safe harbor would not protect ownership or investment interests or remuneration from third parties outside the VBE. However, OIG is considering for the final rule whether to protect ownership or investment interests relating to VBEs that must contract with a payor on behalf of VBE participants for purposes of value-based arrangements with full financial risk.

Proposed New Stark Law Definitions and Exceptions

The value based portion of the proposed rule issued by CMS largely mirrors the OIG’s proposed safe-harbors and corresponding definitions and creates three new exceptions to the physician self-referral law. The exceptions would apply to value-based arrangements between a VBE and one or more of its VBE participants or between parties in the same VBE. It is also notable that CMS is considering following the OIG’s lead and excluding the following providers, suppliers, and other persons from the definition of “VBE participant”: laboratories; pharmaceutical manufacturers; manufacturers, suppliers, and distributors of DMEPOS; pharmacy benefit managers; wholesalers; and distributors.

Only arrangements reasonably designed to achieve at least one value-based purpose related to a target patient population may qualify as a value-based arrangement under the proposed exceptions. However, the proposed exceptions would not protect payments for referrals or any other actions or business unrelated to the target patient population.

CMS believes that arrangements where a physician is at meaningful financial risk for achieving quality and performance based goals contain “certain inherent protections against program or patient abuse.” As a result, similar to the OIG proposal, value-based arrangements that assume greater risk are given increased regulatory flexibility.

Proposed exception for full financial risk

The full financial risk exception would apply to value-based arrangements between VBE participants in a VBE that has assumed “full financial risk” for the cost of all patient care items and services covered by the applicable payor for each patient in the target patient population during the entire duration of the value-based arrangement. The financial risk must be prospective, which prohibits any additional payment to compensate the VBE for costs incurred in providing items and services to the target patient population.

However, any remuneration cannot serve as an inducement to reduce or limit medically necessary items or services to any patient. Moreover, the exception would only protect value-based arrangements where remuneration is not conditioned on referrals of patients who are not part of the target patient population or business not covered under the value-based arrangement.

In the proposed rule, CMS outlines a number of ways a VBE may assume legal obligations, which include, but are not limited, to the following options: (i) VBE participants could each sign a contract for the VBE to assume full financial risk from a payor; (ii) VBE participants could have contractual arrangements among themselves that assign risk jointly and severally; or (iii) VBE participants could also vest the authority to bind all VBE participants in a designated individual who contracts for the assumption of full financial risk on behalf of the VBE and the VBE participants.

Proposed exception for meaningful downside financial risk

This proposed exception would protect remuneration paid under a value-based arrangement where the physician is at “meaningful downside financial risk” for failure to achieve the value-based purpose of the VBE for the entire term of the value-based arrangement. Under the proposed rule “meaningful downside financial risk” means that the physician is responsible to pay a minimum of 25 percent of the value of the remuneration the physician receives under the value-based arrangement.

In addition to the applicable requirements set forth in the exception for full financial risk, the nature and extent of the physician’s financial risk must be set forth in writing. In addition, the methodology used to determine the amount of the remuneration must be set in advance prior to the furnishing of the items or services for which the remuneration is provided.

Proposed exception for value-based arrangements

The proposed exception for value-based arrangements would protect compensation arrangements that qualify as value-based arrangements, regardless of the level of risk undertaken by the VBE or any of the VBE participants. However, given that the exception could potentially protect arrangements where neither party has assumed any financial risk, CMS has stated that there is a need for safeguards in addition to those found under the exception for meaningful downside financial risk in order to guard against patient and program abuse.

As a result, the value-based arrangement is required to be set forth in a writing and signed by the parties, which includes a description of: (i) the value-based activities; (ii) how the value-based activities are expected to further the value-based purpose of the VBE; (iii) the target patient population for the arrangement; (iv) the type or nature of the remuneration; (v) the methodology used to determine the amount of the remuneration; and (vi) the performance or quality standards against which the recipient of the remuneration will be measured, if any.

In addition, CMS is considering whether to prohibit non-monetary remuneration as well as remuneration that is conditioned on the volume or value of referrals of any patients or the volume or value of any other business generated by the physician under the exception. Further, CMS notes that the exception would not protect a “side” arrangement between two VBE participants that is unrelated to the value-based purposes of the VBE, even if such arrangement serves a value-based purpose.

Indirect Compensation Arrangements

The prohibitions found under the Stark Law apply to compensation arrangements involving direct remuneration as well as indirect remuneration. Under the current regulations, if an indirect compensation arrangement exists, the only exception that would protect the compensation arrangement is the “indirect compensation exception.” CMS anticipates that an “unbroken chain of financial relationships” that includes a value-based arrangement could form an “indirect compensation arrangement” under the Stark Law. However, an indirect compensation arrangement that includes a value-based arrangement may not satisfy the requirements of the indirect compensation exception because the compensation paid to a physician may take into account the volume or value of referrals or other business generated by the physician or the compensation may not meet fair market value standards.

Under the proposed rule, when the value-based arrangement is the link in the chain closest to the physician, where the physician is a direct party to the value-based arrangement, the indirect compensation arrangement would qualify as a value-based arrangement for purposes of applying the proposed value-based exceptions. Under this proposal, parties would determine if an indirect compensation arrangement exists and, if it does, determine whether the compensation arrangement to which the physician is a direct party qualifies as a value-based arrangement. If so, the exceptions proposed at 42 C.F.R. § 411.357(aa) for value-based arrangements would be applicable to protect indirect compensation arrangements.

As an alternative option, CMS is proposing to create a new definition referred to as an “indirect value-based arrangement” and specify that the exceptions proposed would be available to protect the arrangement. Under such an approach, an indirect value-based arrangement would exist if: (1) between the physician and the entity there exists an unbroken chain of any number of persons that have financial relationships between them; (2) the financial relationship between the physician and the person with whom he or she is directly linked is a value-based arrangement; and (3) the entity has actual knowledge of the value-based arrangement. If an unbroken chain of financial relationships between a physician and an entity qualifies as an “indirect value-based arrangement,” the three value-based exceptions be applicable.

Key Takeaways

  • No Protection for Arrangements with Pharmaceutical Manufacturers, Labs, and DMEPOS Suppliers

As discussed above, the OIG’s VBE participant exclusions leave pharmaceutical manufacturers, laboratories and DMEPOS Suppliers out in the cold. However, HHS may address value-based arrangements with pharmaceutical manufacturers in future rulemaking, and HHS Secretary Alex Azar has publicly stated that the OIG is working on protections for value-based outcome payments for pharmaceutical products. The OIG’s request for additional comments means that pharmacies, device manufacturers, PBMs, and wholesalers also may risk exclusion. We would expect that representatives and stakeholders for these industries will provide vigorous comments on the final rule addressing these exclusions and proposed exclusions. 

  • Technical Requirements and Monitoring and Oversight Responsibilities

While the proposed rules represent welcome relief and guidance to further the adoption of value-based arrangements, the detailed compliance requirements, monitoring, and oversight required by the rules may present challenges for providers. Many of the requirements and protections imposed by the OIG may prove to be difficult to implement in practice, and we expect that many stakeholder comments will focus on a need for increased flexibility.

[View source.]

Written by:

Mintz - Health Care Viewpoints

Mintz - Health Care Viewpoints on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.